查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2048162

克拉黴素市場－全球產業規模、佔有率、趨勢、機會、預測：銷售管道、最終用途、地區和競爭格局分類，2021-2031年

Clarithromycin Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Sales Channel, By End Use, By Region & Competition, 2021-2031F
出版日期: | 出版商: TechSci Research | 英文 182 Pages | 商品交期: 2-3個工作天內

價格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

簡介目錄

全球克拉黴素市場預計將從 2025 年的 3.4517 億美元成長到 2031 年的 4.2307 億美元，複合年成長率為 3.45%。

克拉黴素作為一種半合成大環內酯類抗生素，其廣泛應用推動了克拉黴素市場的成長。該藥物對多種細菌感染疾病有效，包括呼吸系統和皮膚感染疾病。此外，克拉黴素仍然是根除幽門螺旋桿菌聯合治療的重要組成部分，而社區獲得性肺炎、慢性支氣管炎急性發作和持續性消化性潰瘍等疾病負擔的加重也促進了其需求。

市場概覽
預測期 2027-2031
市場規模：2025年 3.4517億美元
市場規模：2031年 4.2307億美元
複合年成長率：2026-2031年 3.45%
成長最快的細分市場 直接地
最大的市場 北美洲

然而，由於抗生素抗藥性日益嚴重，市場正面臨嚴峻挑戰。這嚴重威脅到藥物的長期臨床療效，並促使醫療專業人員探索替代治療方法。診斷與實驗室醫學會2025年的最新監測數據進一步凸顯了這項挑戰。數據顯示，在高盛行率病患小組中，幽門螺旋桿菌對克拉黴素的平均抗藥性率為32.4%，顯示維持標準根除方案的有效性越來越困難。

市場促進因素

全球克拉黴素市場的主要驅動力是細菌性呼吸道和皮膚感染疾病發生率的上升。克拉黴素在治療社區感染疾病和各種皮膚感染疾病發揮重要作用，這主要歸功於其對非典型病原體的顯著療效。此外，呼吸道疾病的頻繁爆發也需要快速、廣效的抗生素治療，進一步推高了克拉黴素的需求。例如，根據美國疾病管制與預防中心 (CDC) 2025 年 8 月發布的報告，2024 年住院兒童中黴漿菌肺炎的發生率飆升至每 1,000 名住院兒童 12.5 例。這表明需求量的成長導致克拉黴素需​​求增加，從而鞏固了主要供應商的市場地位。例如，山德士 (Sandoz) 在 2024 年實現了 9% 的成長，淨銷售額達到 104 億美元。

第二個關鍵促進因素是新興市場醫療保健支出增加和基礎設施改善。在開發中國家，尤其是在亞洲和中東，醫療保健系統的現代化使患者更容易獲得成熟的品牌學名藥，從而緩解了已開發地區藥品供應飽和的狀況。這些市場受益於公共投資的增加以及越來越多的人能夠負擔得起治療常見感染疾病的必要抗生素治療。雅培巴基斯坦製藥部門2024年銷售額成長22.1%印證了這一趨勢，凸顯了這些高成長經濟體對感染疾病藥物的強勁需求，並表明儘管存在抗藥性方面的擔憂，克拉黴素的全球臨床意義仍將持續存在。

市場挑戰

阻礙全球克拉黴素市場擴張的主要障礙是抗菌藥物抗藥性（AMR）的蔓延，這從根本上削弱了該藥物的臨床效用。隨著細菌病原體對大環內酯類抗生素產生抗藥性機制，醫療專業人員不得不擴大使用四環黴素和Fluoroquinolones等替代療法，以確保患者獲得有效的治療效果。這種對克拉黴素治療方案的轉變直接降低了其在呼吸道和胃腸道感染疾病治療領域的市場佔有率，使其從第一線治療藥物轉變為某些非抗藥性病例的二線治療藥物。此外，嚴格的全球抗菌藥物管理計畫進一步限制了克拉黴素的使用，以維持其剩餘的療效。

這一不利趨勢得到了近期來自主要區域市場的臨床監測數據的支持。美國感染疾病學會 (IDSA) 報告稱，到 2025 年，西太平洋地區黴漿菌分離株的大環內酯類抗藥性可能高達 90%。如此高的抗藥性使得克拉黴素在這些高需求患者群體的經驗性治療中幾乎無效，患者數量的下降直接限制了收入潛力，並對受影響地區的市場滲透構成重大障礙，從而給生產商帶來了不穩定的商業環境。

市場趨勢

推動克拉黴素需​​求成長的關鍵趨勢是基於伏諾拉生的三重聯合治療的日益普及，這正在重塑幽門螺旋桿菌感染疾病的治療模式。這種治療方法的演變在於用鉀離子競爭性抑酸劑（P-CABs，例如伏諾拉生）取代傳統的質子幫浦阻斷劑（PPIs），並與克拉黴素和阿莫西林聯合使用，從而實現更優的抑酸效果和更高的根除率。 P-CABs改善了胃內pH環境，增強了克拉黴素的穩定性和療效，從而解決了抗生素抗藥性的新問題，並提升了該藥物的臨床意義。近期商業數據顯示，這些新療法已迅速佔領市場。據 Phathom Pharmaceuticals 公司稱，其「Voquezna」產品（包括含克拉黴素的聯合包裝療法）的總處方箋已超過 30 萬張，與上一個報告期相比成長了 110%。

同時，全球原料藥供應鏈的策略多角化正成為關鍵的市場趨勢，其驅動力在於製造商努力降低生產設施集中（尤其是在亞洲）所帶來的風險。為了增強韌性並確保基本藥物的穩定供應，製藥公司正在加大投資，在歐洲和北美建立在地化和冗餘的生產能力。這種「中國+1」策略正在從根本上改變大環內酯類抗生素的採購結構，資金正被用於符合區域醫療自主目標的設施升級和擴建項目。歐洲原料藥協會（EuroAPI）2024年的1.08億歐元資本支出計畫便印證了這一點，其中53%專門用於旨在擴大原料藥產能的成長項目。

目錄

第1章概述

第2章：調查方法

第3章執行摘要

第4章：客戶心聲

第5章：全球克拉黴素市場展望

  • 市場規模及預測
    • 按金額
  • 市佔率及預測
    • 銷售管道（直接、間接）
    • 用途（肺炎、支氣管炎、耳部感染疾病、皮膚感染疾病、咽喉感染疾病等）
    • 按地區
    • 按公司（2025 年）
  • 市場地圖

第6章：北美克拉黴素市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 北美洲：國別分析
    • 美國
    • 加拿大
    • 墨西哥

第7章：歐洲克拉黴素市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 歐洲：國別分析
    • 德國
    • 法國
    • 英國
    • 義大利
    • 西班牙

第8章：亞太地區克拉黴素市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 亞太地區：國別分析
    • 中國
    • 印度
    • 日本
    • 韓國
    • 澳洲

第9章：克拉黴素在中東和非洲的市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 中東與非洲：國別分析
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 南非

第10章：克拉黴素在南美洲的市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 南美洲：國別分析
    • 巴西
    • 哥倫比亞
    • 阿根廷

第11章 市場動態

  • 促進因素
  • 任務

第12章 市場趨勢與發展

  • 併購
  • 產品發布
  • 近期趨勢

第13章：全球克拉黴素市場：SWOT分析

第14章：波特五力分析

  • 產業競爭
  • 新進入者的潛力
  • 供應商的議價能力
  • 顧客權力
  • 替代品的威脅

第15章 競爭格局

  • Teva Pharmaceutical Industries Ltd.
  • Novartis AG
  • Sun Pharmaceutical Industries Ltd.
  • Cipla Limited
  • Aurobindo Pharma Limited
  • Zydus Lifesciences Ltd.
  • Pfizer Inc.
  • Dr. Reddy's Laboratories Ltd.
  • Hikma Pharmaceuticals PLC
  • Mylan NV

第16章 策略建議

第17章：關於研究公司及免責聲明

簡介目錄
Product Code: 28250

The Global Clarithromycin Market is projected to expand from USD 345.17 Million in 2025 to USD 423.07 Million by 2031, demonstrating a Compound Annual Growth Rate of 3.45%. This growth is underpinned by clarithromycin's extensive use as a semi-synthetic macrolide antibiotic, effective against a broad array of bacterial infections including those affecting the respiratory tract and skin. Furthermore, it remains a vital component in combination therapies for eradicating Helicobacter pylori, with sustained demand driven by the increasing prevalence of community-acquired pneumonia, acute exacerbations of chronic bronchitis, and the persistent burden of peptic ulcer disease.

Market Overview
Forecast Period2027-2031
Market Size 2025USD 345.17 Million
Market Size 2031USD 423.07 Million
CAGR 2026-20313.45%
Fastest Growing SegmentDirect
Largest MarketNorth America

However, the market faces a significant hurdle due to the escalating rates of antimicrobial resistance, which poses a considerable threat to the drug's long-term clinical effectiveness and prompts healthcare providers to seek alternative treatments. This challenge is underscored by recent surveillance data from the Association for Diagnostics & Laboratory Medicine in 2025, which indicated an average resistance rate of 32.4% for Helicobacter pylori to clarithromycin in high-prevalence patient groups, highlighting the growing difficulty in maintaining standard eradication protocol efficacy.

Market Driver

The primary catalyst for the global clarithromycin market is the escalating incidence of bacterial respiratory tract and skin infections. Clarithromycin maintains its crucial role in treating conditions such as community-acquired pneumonia and various skin infections, largely due to its proven efficacy against atypical pathogens, with demand further intensified by periodic outbreaks of respiratory illnesses that necessitate rapid, widespread antibiotic deployment. For instance, a Centers for Disease Control and Prevention report from August 2025 revealed that the incidence of Mycoplasma pneumoniae-associated pneumonia in hospitalized children surged to 12.5 per 1,000 hospitalizations in 2024, demonstrating a volume-driven demand that strengthens the market position of key suppliers, as evidenced by Sandoz's 9% growth and USD 10.4 billion net sales in 2024.

A second significant driver is the increasing healthcare expenditure and improving infrastructure across emerging markets. Developing nations, particularly in Asia and the Middle East, are modernizing their healthcare systems, thereby enhancing patient access to established branded generics and offsetting saturation observed in more developed regions. These markets benefit from growing public investments and a broader demographic capable of affording essential antibiotic courses for common infections, a trend exemplified by Abbott Pakistan's pharmaceutical division sales rising by 22.1% in 2024, underscoring the robust uptake of anti-infective treatments in these high-growth economies and ensuring clarithromycin's continued global clinical relevance despite resistance concerns.

Market Challenge

The predominant obstacle hindering the expansion of the Global Clarithromycin Market is the rising prevalence of antimicrobial resistance (AMR), which fundamentally undermines the drug's clinical utility. As bacterial pathogens develop resistance mechanisms against macrolide antibiotics, medical professionals are increasingly forced to prescribe alternative therapeutic classes, such as tetracyclines or fluoroquinolones, to ensure effective patient outcomes. This shift away from clarithromycin directly diminishes its market share in the treatment of respiratory and gastric infections, reclassifying it from a first-line therapy to a second-tier option for specific, non-resistant cases, with stringent global antimicrobial stewardship programs further restricting its usage to preserve its remaining efficacy.

This detrimental trend is reinforced by recent clinical surveillance data from key regional markets, where, in 2025, the Infectious Diseases Society of America reported macrolide resistance rates among Mycoplasma pneumoniae isolates reaching up to 90% in the Western Pacific region. Such high resistance levels render clarithromycin largely ineffective for empirical therapy in these high-demand populations, creating a volatile operational environment for manufacturers, as a shrinking patient base directly constrains revenue potential and erects significant barriers to market penetration in affected geographic areas.

Market Trends

A pivotal trend reshaping the treatment landscape for Helicobacter pylori infection, a crucial demand driver for clarithromycin, is the increasing adoption of vonoprazan-based triple therapy regimens. This therapeutic evolution involves replacing conventional proton pump inhibitors with potassium-competitive acid blockers (P-CABs) like vonoprazan, which are then combined with clarithromycin and amoxicillin, leading to superior acid suppression and higher eradication rates. The improved intragastric pH environment provided by P-CABs enhances clarithromycin's stability and efficacy, thereby addressing emerging concerns related to antibiotic resistance and bolstering the drug's clinical relevance. The rapid market integration of these novel regimens is evident in recent commercial figures, with Phathom Pharmaceuticals reporting over 300,000 total filled prescriptions for its Voquezna products, including clarithromycin-based co-packaged therapies, demonstrating a 110% increase over the prior reporting period.

Concurrently, the Strategic Diversification of Global API Supply Chains has emerged as a crucial market trend, driven by manufacturers' efforts to mitigate risks associated with concentrated production facilities, particularly in Asia. To enhance resilience and ensure a stable supply of essential medicines, pharmaceutical companies are increasingly investing in establishing localized and redundant manufacturing capabilities across Europe and North America. This "China Plus One" strategy is fundamentally altering procurement dynamics for macrolide antibiotics, directing capital toward facility upgrades and expansion projects that align with objectives for regional health sovereignty, as reflected by EuroAPI's 2024 capital expenditures of EUR 108 million, with 53% specifically allocated to growth projects aimed at expanding active pharmaceutical ingredient production capacities.

Key Market Players

  • Teva Pharmaceutical Industries Ltd.
  • Novartis AG
  • Sun Pharmaceutical Industries Ltd.
  • Cipla Limited
  • Aurobindo Pharma Limited
  • Zydus Lifesciences Ltd.
  • Pfizer Inc.
  • Dr. Reddy's Laboratories Ltd.
  • Hikma Pharmaceuticals PLC
  • Mylan N.V.

Report Scope

In this report, the Global Clarithromycin Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Clarithromycin Market, By Sales Channel

  • Direct
  • Indirect

Clarithromycin Market, By End Use

  • Pneumonia
  • Bronchitis
  • Ear Infection
  • Skin Infection
  • Throat Infection
  • Others

Clarithromycin Market, By Region

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • United Kingdom
    • Italy
    • Germany
    • Spain
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Clarithromycin Market.

Available Customizations:

Global Clarithromycin Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Clarithromycin Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Sales Channel (Direct, Indirect)
    • 5.2.2. By End Use (Pneumonia, Bronchitis, Ear Infection, Skin Infection, Throat Infection, Others)
    • 5.2.3. By Region
    • 5.2.4. By Company (2025)
  • 5.3. Market Map

6. North America Clarithromycin Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Sales Channel
    • 6.2.2. By End Use
    • 6.2.3. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Clarithromycin Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Sales Channel
        • 6.3.1.2.2. By End Use
    • 6.3.2. Canada Clarithromycin Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Sales Channel
        • 6.3.2.2.2. By End Use
    • 6.3.3. Mexico Clarithromycin Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Sales Channel
        • 6.3.3.2.2. By End Use

7. Europe Clarithromycin Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Sales Channel
    • 7.2.2. By End Use
    • 7.2.3. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. Germany Clarithromycin Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Sales Channel
        • 7.3.1.2.2. By End Use
    • 7.3.2. France Clarithromycin Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Sales Channel
        • 7.3.2.2.2. By End Use
    • 7.3.3. United Kingdom Clarithromycin Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Sales Channel
        • 7.3.3.2.2. By End Use
    • 7.3.4. Italy Clarithromycin Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Sales Channel
        • 7.3.4.2.2. By End Use
    • 7.3.5. Spain Clarithromycin Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Sales Channel
        • 7.3.5.2.2. By End Use

8. Asia Pacific Clarithromycin Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Sales Channel
    • 8.2.2. By End Use
    • 8.2.3. By Country
  • 8.3. Asia Pacific: Country Analysis
    • 8.3.1. China Clarithromycin Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Sales Channel
        • 8.3.1.2.2. By End Use
    • 8.3.2. India Clarithromycin Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Sales Channel
        • 8.3.2.2.2. By End Use
    • 8.3.3. Japan Clarithromycin Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Sales Channel
        • 8.3.3.2.2. By End Use
    • 8.3.4. South Korea Clarithromycin Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Sales Channel
        • 8.3.4.2.2. By End Use
    • 8.3.5. Australia Clarithromycin Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Sales Channel
        • 8.3.5.2.2. By End Use

9. Middle East & Africa Clarithromycin Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Sales Channel
    • 9.2.2. By End Use
    • 9.2.3. By Country
  • 9.3. Middle East & Africa: Country Analysis
    • 9.3.1. Saudi Arabia Clarithromycin Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Sales Channel
        • 9.3.1.2.2. By End Use
    • 9.3.2. UAE Clarithromycin Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Sales Channel
        • 9.3.2.2.2. By End Use
    • 9.3.3. South Africa Clarithromycin Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Sales Channel
        • 9.3.3.2.2. By End Use

10. South America Clarithromycin Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Sales Channel
    • 10.2.2. By End Use
    • 10.2.3. By Country
  • 10.3. South America: Country Analysis
    • 10.3.1. Brazil Clarithromycin Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Sales Channel
        • 10.3.1.2.2. By End Use
    • 10.3.2. Colombia Clarithromycin Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Sales Channel
        • 10.3.2.2.2. By End Use
    • 10.3.3. Argentina Clarithromycin Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Sales Channel
        • 10.3.3.2.2. By End Use

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Merger & Acquisition (If Any)
  • 12.2. Product Launches (If Any)
  • 12.3. Recent Developments

13. Global Clarithromycin Market: SWOT Analysis

14. Porter's Five Forces Analysis

  • 14.1. Competition in the Industry
  • 14.2. Potential of New Entrants
  • 14.3. Power of Suppliers
  • 14.4. Power of Customers
  • 14.5. Threat of Substitute Products

15. Competitive Landscape

  • 15.1. Teva Pharmaceutical Industries Ltd.
    • 15.1.1. Business Overview
    • 15.1.2. Products & Services
    • 15.1.3. Recent Developments
    • 15.1.4. Key Personnel
    • 15.1.5. SWOT Analysis
  • 15.2. Novartis AG
  • 15.3. Sun Pharmaceutical Industries Ltd.
  • 15.4. Cipla Limited
  • 15.5. Aurobindo Pharma Limited
  • 15.6. Zydus Lifesciences Ltd.
  • 15.7. Pfizer Inc.
  • 15.8. Dr. Reddy's Laboratories Ltd.
  • 15.9. Hikma Pharmaceuticals PLC
  • 15.10. Mylan N.V.

16. Strategic Recommendations

17. About Us & Disclaimer